Given the evolving landscape of therapeutic options for RAIR-DTC, it is essential to highlight the importance of timely evaluating patients with advanced thyroid cancer.
Read More
Thyroid cancers (TC) are driven by a handful of genetic alterations. Papillary TC primarily harbors mutations involving BRAF, RAS or RET genes.
Medullary thyroid cancer (MTC) is a rare thyroid malignancy and considered a neuroendocrine type of tumor.
There are limited number of studies that have examined patients preferences concerning treatment options for patients with thyroid cancer.
Thyroid cancer in pediatric patients is not a rare entity, in fact it is the most common non-CNS solid tumor in childhood.
Familial non-medullary thyroid cancer (FNMTC) constitutes 3–9% of all thyroid cancer cases and is divided into syndromic and non-syndromic FNMTC.
After receiving a diagnosis of papillary thyroid cancer, intuitively, the thought has been that surgery is the next step. While this was the standard in the past, we now know that in specific situations immediate surgery may not be necessary.
Thyroid Journal Program Thyroid®, Clinical Thyroidology®, and VideoEndocrinology™ Latest Impact Factor: 5.309 Special Collection: Virtual Review…
New guidelines for the diagnosis, evaluation, and treatment of anaplastic thyroid cancer (ATC) reflect the significant clinical and scientific advances that have occurred in the field since the previous guidelines were released. The American Thyroid Association® (ATA®) ATC Guidelines Task Force presents the new guidelines in the peer-reviewed journal Thyroid®, the official journal of the American Thyroid Association® (ATA®). Click here to read the Guidelines now.
From Clinical Thyroidology® for the Public: As more patients are receiving organ transplants, it is…
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.